Company Valuation: GC Genome Corporation

Data adjusted to current consolidation scope
Fiscal Period: December 2025 2026 2027
Market Cap 1 161,298 133,154 -
Change - -17.45% -
Enterprise Value (EV) 1 161.3 73.75 64.35
Change - -54.27% -12.75%
P/E 36.9x - -
PBR - - -
PEG -0x - -
Capitalization / Revenue - 3.41x 2.73x
EV / Revenue - 1.89x 1.32x
EV / EBITDA - - -
EV / EBIT - 18.4x 9.19x
EV / FCF - - -
FCF Yield - - -
Dividend per Share 3 - - -
Rate of return - - -
EPS 3 185 - -
Distribution rate - - -
Net sales 1 - 39 48.8
EBITDA - - -
EBIT 1 - 4 7
Net income 4.044 - -
Net Debt 1 - -59.4 -68.8
Reference price 3 6,820.00 5,630.00 5,630.00
Nbr of stocks (in thousands) 23,651 23,651 -
Announcement Date 3/16/26 - -
1KRW in Million2KRW in Billions3KRW
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- 2.05x - - 102M
-234.01x15.55x-278.7x-.--% 46.24B
23.51x2.15x12.15x0.89% 26.57B
16.02x1.26x7.18x5.47% 6.94B
1078.86x - - - 5.94B
51.51x9.49x32.7x0.97% 3.35B
-25.28x - - - 2.53B
-58.45x - - -.--% 2.24B
14.5x1.47x5.77x5.25% 2.03B
30.88x1.63x12.2x1.46% 1.88B
Average 99.73x 4.80x -34.78x 2.01% 9.78B
Weighted average by Cap. -36.90x 9.45x -142.15x 0.88%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. A340450 Stock
  4. Valuation GC Genome Corporation